Cargando…

HIV-1 prophylactic vaccines: state of the art

The quest for an effective HIV-1 vaccine began early in the course of the HIV pandemic. Over time, the paradigm has evolved from B cell- towards T cell-based vaccines. Results from initial Phase II/III trials have been disappointing; however, while modest, the unexpected results of the Phase II/III...

Descripción completa

Detalles Bibliográficos
Autores principales: Lelièvre, Jean-Daniel, Lévy, Yves
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Mediscript Ltd 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4946697/
https://www.ncbi.nlm.nih.gov/pubmed/27482428